50534-11-7

Basic information

• Product Name: 4-amino-N-(1-methylpiperidin-4-yl)benzamide
• Synonyms: 4-amino-N-(1-methylpiperidin-4-yl)benzamide
• CAS NO: 50534-11-7
• Molecular Weight: 233.313
• Mol File: 50534-11-7.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: 4-amino-N-(1-methylpiperidin-4-yl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-amino-N-(1-methylpiperidin-4-yl)benzamide(50534-11-7)
• EPA Substance Registry System: 4-amino-N-(1-methylpiperidin-4-yl)benzamide(50534-11-7)

Safety Data

• Hazardous Substances Data: 50534-11-7(Hazardous Substances Data)

Upstream product

• 62-23-7 4-nitro-benzoic acid 
• 150-13-0 4-amino-benzoic acid 
• 66493-39-8 4-(N-tert-butoxycarbonyl)aminobenzoic acid 
• 41838-46-4 4-Amino-1-methylpiperidine 
• 1445-73-4 1-Methyl-4-piperidone 
• 210643-97-3 N-(1-methylpiperidin-4-yl)-4-nitrobenzamide 

Downstream Products

• 946822-72-6 (rac)-4-(9-cyclopentyl-5,7-dimethyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-N-(1-methyl-piperidin-4-yl)-benzamide 
• 1254783-19-1 C₂₆H₂₇ClN₆O₃ 
• 1350545-36-6 4-(4-isopropylamino-5-nitropyrimidin-2-ylamino)-N-(1-methylpiperidin-4-yl)benzamide 
• 1201692-28-5 4-(9-cyclopentyl-7,7-difluoro-6-oxo-5-propyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-N-(1-methyl-piperidin-4-yl)-benzamide 
• 1201692-22-9 4-(9-cyclopentyl-5-ethyl-7,7-difluoro-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-N-(1-methyl-piperidin-4-yl)-benzamide 
• 1201691-20-4 4-(9-cyclobutyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-N-(1-methyl-piperidin-4-yl)-benzamide 
• 1201692-15-0 4-(9-cyclopentyl-7,7-difluoro-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-N-(1-methyl-piperidin-4-yl)-benzamide 
• 1117685-37-6 4-[4-(2,6-dimethylpyridin-3-yloxy)pyridin-2-ylamino]-N-(1-methylpiperidin-4-yl)benzamide 

Relevant articles and documents

PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER

The invention provides compounds of the formula (1): or a salt or tautomer thereof wherein A, R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds are inhibitors of Wee1 and/or PLK1 kinase and are envisaged to be useful in the treatment of cancers.

Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model

FLT3 mutation is among the most common genetic mutations in acute myeloid leukemia (AML), which is also related with poor overall survival and refractory in AML patients. Recently, FLT3 inhibitors have been approved for AML therapy. Herein, a series of new compounds with pyrazole amine scaffold was discovered, which showed potent inhibitory activity against FLT3-ITD and significant selectivity against both FLT3-ITD and AML cells expressing FLT3-ITD. Compound 46, possessing the most promising cellular activity, blocked the autophosphorylation of FLT3 pathway in MV4-11 cell line. Furthermore, the apoptosis and downregulation of P-STAT5 were also observed in tumor cells extracted from the MV4-11 cell xenografts model upon compound 46 treatment. Compound 46 was also metabolically stable in vitro and suppressed tumor growth significantly in MV4-11 xenografts model in vivo. Compound 46 showed no toxicity to the viscera of mice and caused no decrease in body weight of mice. In conclusion, the results of this study could provide valuable insights into discovery of new FLT3 inhibitors, and compound 46 was worthy of further development as potential drug candidate to treat AML.

BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS

Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.